Traditional phase 1 and 2 studies in thoracic radiation oncology should be abandoned.
Affiliation
Institute of Cancer Sciences, University of Manchester, Radiotherapy Related Research, The Christie NHS Foundation Trust, Manchester, United Kingdom.Issue Date
2014-11-01
Metadata
Show full item recordCitation
Traditional phase 1 and 2 studies in thoracic radiation oncology should be abandoned. 2014, 90 (3):487-9 Int J Radiat Oncol Biol PhysJournal
International Journal of Radiation Oncology, Biology, PhysicsDOI
10.1016/j.ijrobp.2014.05.044PubMed ID
25304944Type
ArticleLanguage
enISSN
1879-355Xae974a485f413a2113503eed53cd6c53
10.1016/j.ijrobp.2014.05.044
Scopus Count
Collections
Related articles
- Clinical trials in thoracic radiation oncology: as easy as 1, 2, 3.
- Authors: Machtay M, Bradley JD, Curran WJ
- Issue date: 2014 Nov 1
- Pembrolizumab Outperforms Docetaxel for NSCLC.
- Authors: Leslie M
- Issue date: 2016 Mar
- Concurrent chemoradiotherapy followed by consolidation chemotherapy with bi-weekly docetaxel and carboplatin for stage III unresectable, non-small-cell lung cancer: clinical application of a protocol used in a previous phase II study.
- Authors: Saitoh J, Saito Y, Kazumoto T, Kudo S, Yoshida D, Ichikawa A, Sakai H, Kurimoto F, Kato S, Shibuya K
- Issue date: 2012 Apr 1
- Current status of and future strategies for multimodality treatment of unresectable stage III nonsmall cell lung cancer.
- Authors: Huber RM, Reck M, Thomas M
- Issue date: 2013 Oct
- Is immune checkpoint inhibition part of standard therapy for stage III non-small cell lung cancer?
- Authors: Patel JD, Chmura SJ
- Issue date: 2018 Jul 15